Objective & Strategy
The fund seeks long-term growth of capital by investing in equity securities of health care companies throughout the world.
Morningstar Rating ™
Overall Rating - Health CategoryAs of 06/30/2020 the Fund had an overall rating of 3 stars out of 135 funds and was rated 3 stars out of 135 funds, 3 stars out of 125 funds and 2 stars out of 104 funds for the 3-, 5- and 10- year periods, respectively.
Source: Morningstar Inc. Ratings are based on a risk-adjusted return measure that accounts for variation in a fund's monthly performance, placing more emphasis on downward variations and rewarding consistent performance. Open-end mutual funds and exchange-traded funds are considered a single population for comparison purposes. Ratings are calculated for funds with at least a three year history. The overall rating is derived from a weighted average of three-, five- and 10-year rating metrics, as applicable, excluding sales charges and including fees and expenses. ©2020 Morningstar Inc. All rights reserved. The information contained herein is proprietary to Morningstar and/or its content providers. It may not be copied or distributed and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance does not guarantee future results. The top 10% of funds in a category receive five stars, the next 22.5% four stars, the next 35% three stars, the next 22.5% two stars and the bottom 10% one star. Ratings are subject to change monthly. Had fees not been waived and/or expenses reimbursed currently or in the past, the Morningstar rating would have been lower. Ratings for other share classes may differ due to different performance characteristics.
Management team
-
Henry Wu
Portfolio Manager
Top Equity Holdings | View all
| % of Total Assets | |
|---|---|
| Thermo Fisher Scientific | 5.09 |
| UnitedHealth | 4.79 |
| Novartis ADR | 4.14 |
| AstraZeneca | 4.14 |
| Johnson & Johnson | 4.07 |
| Medtronic | 3.51 |
| Eli Lilly | 3.05 |
| Vertex Pharmaceuticals | 2.91 |
| Sanofi ADR | 2.77 |
| Abbott Laboratories | 2.67 |
May not equal 100% due to rounding.
Holdings are subject to change and are not buy/sell recommendations.
Average Annual Returns (%)
| Incept. Date |
Max Load (%) |
Since Incept. (%) |
YTD (%) | 1Y (%) | 3Y (%) | 5Y (%) | 10Y (%) | |
|---|---|---|---|---|---|---|---|---|
| NAV | 08/07/1989 | N/A | 10.66 | -2.65 | 11.51 | 9.29 | 3.94 | 12.77 |
| Load | 08/07/1989 | 5.50 | 10.45 | -8.00 | 5.38 | 7.25 | 2.77 | 12.13 |
| NAV | 08/07/1989 | N/A | 10.66 | -2.65 | 11.51 | 9.29 | 3.94 | 12.77 |
| Load | 08/07/1989 | 5.50 | 10.45 | -8.00 | 5.38 | 7.25 | 2.77 | 12.13 |
Annualized Benchmark Returns
| Index Name | 1 Mo (%) | 3 Mo (%) | 1Y (%) | 3Y (%) | 5Y (%) | 10Y (%) |
|---|---|---|---|---|---|---|
| MSCI Wld Hlth Cr ND IX | -1.34 | 14.56 | 13.87 | 9.80 | 6.76 | 13.59 |
| MSCI World IX ND | 2.65 | 19.36 | 2.84 | 6.70 | 6.90 | 9.95 |
| MSCI Wld Hlth Cr ND IX | -1.34 | 14.56 | 13.87 | 9.80 | 6.76 | 13.59 |
| MSCI World IX ND | 2.65 | 19.36 | 2.84 | 6.70 | 6.90 | 9.95 |
Source: RIMES Technologies Corp.
Source: RIMES Technologies Corp.
An investment cannot be made directly in an index.
Expense Ratio per Prospectus
| Management Fee | 0.63 |
| 12b-1 Fee | 0.25 |
| Other Expenses | 0.20 |
| Interest/Dividend Exp | 0.00 |
| Total Other Expenses | 0.20 |
| Acquired Fund Fees and Expenses (Underlying Fund Fees & Expenses) | 0.00 |
| Total Annual Fund Operating Expenses | 1.08 |
| Contractual Waivers/Reimbursements | N/A |
| Net Expenses - PER PROSPECTUS | 1.08 |
| Additional Waivers/Reimbursements | 0.00 |
| Net Expenses - With Additional Fee Reduction | 1.08 |
Historical Prices
| Date | Net Asset Value ($) | Public Offering Price ($) |
|---|---|---|
| {{histTableData.rateDate | date : 'MM/dd/yyyy'}} | {{histTableData.netAssetValue | numberValue}} | {{histTableData.offeringPrice | numberValue}} |
Distributions
| Capital Gains | Reinvestment Price ($) |
|||
|---|---|---|---|---|
| Ex-Date | Income | Short Term | Long Term | |
| {{distribution.rateDate | date : 'MM/dd/yyyy'}} | {{distribution.dividendFactor | numberValue:4:'N/A'}} | {{distribution.capGainsFactorShort | numberValue:4:'N/A'}} | {{distribution.capGainsFactorLong | numberValue:4:'N/A'}} | {{distribution.reinvestmentPrice | numberValue:3:'N/A'}} |
Sector Breakdown
| Holdings | % of Total Net Assets |
|---|---|
| CASH/OTHER | 2.30 |
| Consumer Staples | 0.80 |
| Health Care | 96.90 |
May not equal 100% due to rounding.
The holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc. and Standard & Poor's.
Fund Characteristics
| 3-Year Alpha | -1.35% |
| 3-Year Beta | 1.15 |
| 3-Year R-Squared | 0.93 |
| 3-Year Sharpe Ratio | 0.45 |
| 3-Year Standard Deviation | 17.07 |
| Number of Securities | 82 |
| Total Assets | $1,429,312,990.00 |
| Wghtd Med Mkt Cap MM$ | $69,302.00 |
Source: RIMES Technologies Corp.,StyleADVISOR
Benchmark: MSCI Wld Hlth Cr ND IX
Top Equity Holdings | View all
| % of Total Assets | |
|---|---|
| Thermo Fisher Scientific | 5.09 |
| UnitedHealth | 4.79 |
| Novartis ADR | 4.14 |
| AstraZeneca | 4.14 |
| Johnson & Johnson | 4.07 |
| Medtronic | 3.51 |
| Eli Lilly | 3.05 |
| Vertex Pharmaceuticals | 2.91 |
| Sanofi ADR | 2.77 |
| Abbott Laboratories | 2.67 |
May not equal 100% due to rounding.
Holdings are subject to change and are not buy/sell recommendations.
Top Countries
| % of Total Assets | |
|---|---|
| United States | 75.35 |
| Switzerland | 7.06 |
| United Kingdom | 4.42 |
| Denmark | 2.82 |
| France | 2.77 |
| Brazil | 2.16 |
| Netherlands | 1.76 |
| Luxembourg | 0.54 |
| China | 0.39 |
| Australia | 0.34 |
May not equal 100% due to rounding.
Top Industries
| % of Total Assets | |
|---|---|
| Pharmaceuticals | 32.97 |
| Biotechnology | 18.46 |
| Health Care Equipment | 17.53 |
| Managed Health Care | 11.50 |
| Life Sciences Tools & Services | 7.92 |
| Health Care Supplies | 2.77 |
| Health Care Services | 2.68 |
| Health Care Technology | 1.92 |
| Health Care Facilities | 1.10 |
| Drug Retail | 0.47 |
May not equal 100% due to rounding.
The holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc. and Standard & Poor's.
United States
Canada (English)
United Kingdom
Isle of Man
Jersey
Guernsey
Australia
China
Hong Kong
Japan
Taiwan
Europe
Dubai